Mihai Vasile M.
- Country
- Romania
- Department
- Medical Oncology
Research Overview
- Phase 3 Randomized Study of Telisotuzumab Vedotin vs. Docetaxel in c-Met Overexpressing EGFR Wildtype Non-Squamous NSCLC
- A PHASE 2 STUDY EVALUATING INCB099280 IN PARTICIPANTS WITH SELECT SOLID TUMORS WHO ARE IMMUNE CHECKPOINT INHIBITOR–NAÏVE
- An open label, multicenter extension study in patients previously enrolled in a Genentch and/or F. Hoffmann-La Roche Ltd sponsored atezolizumab study (IMBRELLA B)
Data & Insights
Has run more than one trial at 94 of 293 partner sites.
Specializations
Lung Cancer Research
The investigator specializes in treating non-squamous non-small cell lung cancer (NSCLC), with particular focus on cases involving c-Met overexpression and EGFR wildtype variants.
- Advanced NSCLC Treatment Approaches
- Molecular Targeting Therapies
- Biomarker-Driven Treatment Selection
Their expertise extends to evaluating novel therapeutic approaches for previously treated lung cancer patients.
Advanced Solid Tumors
The investigator focuses on developing treatments for recurrent and metastatic solid tumors, with specific interest in immune checkpoint inhibitor-naïve patients.
- Immunotherapy Applications
- Novel Treatment Protocols
- Advanced Disease Management
Their work encompasses evaluation of innovative therapeutic agents for various solid tumor types.
Immunotherapy Research
The investigator specializes in immunotherapeutic approaches for solid tumors, with particular expertise in long-term treatment monitoring and safety assessment.
- Treatment Safety Protocols
- Extended Therapy Management
- Patient Response Monitoring
Their research includes continuous assessment of immunotherapy treatments in various solid tumor contexts.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.